Genovis Launches Immobilized SialEXO® for Efficient Biopharmaceutical Sample Preparation

Dec. 11, 2019 14:00 UTC


LUND, Sweden--(BUSINESS WIRE)-- Genovis enzymes are used as platform methods in analytical workflows using mass spectrometry within the biopharma industry. Immobilized SialEXO benefits mass spectrometry but will significantly impact analytical workflows using capillary electrophoresis (CE). Charge variants of proteins are often analyzed using CE and the technology is well established for protein analysis and quality control. From our collaboration with ProteinSimple, a leading instrument provider, Genovis has developed a product and associated methods that are well adapted to CE instrumentation and routine analysis of proteins. The poster presented at the Antibody Engineering and Therapeutics conference demonstrates rapid sample preparation of a range of biologics followed by analysis using the CE instrument Maurice™ from ProteinSimple. Immobilized SialEXO is available for purchase starting today.

  • Our products are increasingly popular in routine analysis of biologics and Immobilized SialEXO is designed to be robust, fast, and easy-to-use - properties well suited to quality control analysis using for example CE instrumentation. Immobilized SialEXO expands Genovis product line within Glycobiology and is developed based on customer requests and with input from our collaborators. I especially want to thank the team at ProteinSimple for an excellent collaboration regarding the development of application data, comments Fredrik Olsson CEO of Genovis.

More about Immobilized SialEXO
When analyzing biopharmaceuticals, enzymes are often used in sample preparation to simplify the analysis of large and complex molecules such as therapeutic proteins. Proteins are often glycosylated and certain sugar residues could mask underlying protein variations. After 30 minutes incubation, Immobilized SialEXO hydrolyzes the charged sialic acid glycans and enables further analysis without leaving the enzyme in the sample.

Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis’ shares are listed on NASDAQ First North Stockholm and Erik Penser Bank is the Company’s Certified Adviser,, tel: +46 (0)8-463 83 00.

This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.


Fredrik Olsson, CEO, Genovis AB
T: +46 (0)46-12 12 33


Source: Genovis

Back to news